US · CSTL
Castle Biosciences, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Friendswood, TX 77546
- Website
- castlebiosciences.com
Price · as of 2025-12-31
$24.81
Market cap 863.11M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $50.80 | +104.76% |
| Intrinsic Value(DCF) | $20.66 | -16.73% |
| Graham-Dodd Method(GD) | $8.64 | -65.17% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $32.19 | $371.92 | $768,248.51 | $12.99 | $80.03 |
| 2020 | $64.19 | $93.25 | $679.44 | $19.24 | $0.00 |
| 2021 | $39.95 | $204.58 | $676.89 | $10.16 | $0.00 |
| 2022 | $19.47 | $30.75 | $131.47 | $2.02 | $0.00 |
| 2023 | $20.79 | $67.10 | $1,589.30 | $3.48 | $0.00 |
| 2024 | $20.21 | $672.70 | $3,541.45 | $19.31 | $37.38 |
| 2025 | $27.99 | $50.80 | $274.60 | $8.64 | $0.00 |
AI valuation
Our deep-learning model estimates Castle Biosciences, Inc.'s (CSTL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $50.80
- Current price
- $24.81
- AI upside
- +104.76%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$20.66
-16.73% upside
Graham-Dodd
$8.64
-65.17% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CSTL | Castle Biosciences, Inc. | $24.81 | 863.11M | +105% | -17% | -65% | — | -33.58 | 1.72 | 2.36 | 48.38 | — | 2.19 | 68.66% | -12.44% | -7.02% | -5.21% | -17.64% | -4.35% | 0.08 | -497.79 | 5.26 | 4.99 | -7.04 | -23387.00% | 366.00% | -2248.00% | 3.49% | 0.94 | 14.26% | 0.00% | 0.00% | 0.00% | -12.82 | 19.37 | 1.59 | 4.94 |
| AMN | AMN Healthcare Services, … | $19.48 | 748.3M | +170% | -58% | — | — | — | 1.22 | 0.29 | 15.68 | — | -1.98 | 22.93% | 1.21% | -3.51% | 0.00% | 1.94% | 0.00% | 1.30 | 0.73 | 0.94 | 0.72 | 7.90 | -3558.00% | -849.00% | 1250.00% | 34.29% | 0.47 | 16.66% | 0.00% | — | 36.62% | 47.79 | 5.88 | 0.58 | 2.47 |
| CDNA | CareDx, Inc | $18.76 | 964.88M | +90% | -24% | -84% | — | -46.78 | 3.30 | 2.63 | -1261.39 | — | 4.33 | 66.99% | -5.53% | -5.62% | -6.27% | -14.41% | -4.72% | 0.06 | — | 2.86 | 2.45 | 68.59 | -14301.00% | 1379.00% | 1443.00% | 3.62% | 0.47 | 24.76% | 0.00% | 0.00% | 8.79% | -40.03 | 23.29 | 2.22 | 4.19 |
| DRIO | DarioHealth Corp. | $11.97 | 80.9M | +162% | -51% | — | — | -22.91 | 13.60 | 36.23 | -19.50 | — | -234.90 | 49.06% | -213.55% | -158.09% | -65.68% | -88.81% | -39.71% | 0.42 | -601.50 | 2.44 | 2.03 | -0.05 | -6839.00% | 3286.00% | 2499.00% | -3.95% | -2.32 | -62.10% | 0.00% | 0.00% | 0.00% | -16.99 | -25.36 | 36.29 | 6.81 |
| EMBC | Embecta Corp. | $10.26 | 607.6M | +264% | -45% | — | -28% | 6.95 | -1.02 | 0.61 | 6.34 | 33.27 | -0.99 | 62.89% | 30.48% | 8.83% | -13.74% | 39.85% | 8.03% | -2.20 | 3.07 | 2.41 | 1.43 | 4.09 | 2090.00% | -380.00% | 81658.00% | 27.50% | 0.73 | 31.54% | 5.28% | 36.70% | 26.66% | 5.67 | 10.24 | 1.73 | 2.05 |
| EVH | Evolent Health, Inc. | $3.25 | 376.91M | +378% | -56% | — | +2,393% | -0.71 | 0.98 | 0.22 | -0.76 | -0.13 | -0.47 | 15.09% | -0.24% | -28.49% | -81.81% | -0.48% | -26.08% | 0.05 | -0.08 | 1.31 | 1.23 | 0.37 | 52593.00% | -2656.00% | -17759.00% | 1.16% | 0.10 | 0.52% | 2.72% | -1.90% | 194.02% | -62.28 | 58.08 | 0.15 | 0.25 |
| FLGT | Fulgent Genetics, Inc. | $15.33 | 473.89M | +1,814% | -46% | +66% | — | -7.09 | 0.39 | 1.35 | -2.21 | -17.85 | 0.43 | 40.56% | -19.10% | -18.75% | -5.49% | -6.54% | -5.07% | 0.00 | -821.75 | 6.48 | 4.95 | 1.08 | 3972.00% | 1383.00% | 54509.00% | -28.42% | -1.20 | -14.97% | 0.00% | 0.00% | 3.19% | -1.65 | -0.82 | 0.31 | 3.63 |
| GERN | Geron Corporation | $1.68 | 1.07B | +294,119% | -54% | — | — | -6.40 | 3.99 | 14.52 | -5.38 | — | 3.99 | 98.37% | -225.64% | -226.73% | -66.09% | 7931.16% | -35.34% | 0.43 | -9.39 | 5.56 | 5.04 | -0.28 | -1562.00% | 3238692.00% | 3009.00% | -19.62% | -2.48 | 10011.32% | 0.00% | 0.00% | 0.00% | -4.79 | -3.80 | 10.82 | -2.06 |
| MYGN | Myriad Genetics, Inc. | $4.61 | 429.72M | +702% | -57% | — | — | — | 1.27 | 0.57 | -1.33 | — | 2.87 | 69.93% | -16.90% | -44.38% | 0.00% | -22.11% | 0.00% | 0.57 | -11.51 | 2.49 | 1.98 | -0.15 | 18085.00% | -156.00% | -10469.00% | 0.39% | 0.01 | 0.31% | 0.00% | — | 0.00% | -3.79 | 293.13 | 0.64 | -0.54 |
| PSNL | Personalis, Inc. | $9.06 | 804.57M | +263% | — | — | — | -9.95 | 3.10 | — | -8.46 | — | 3.10 | 0.00% | — | — | -35.02% | -152.75% | -26.89% | 0.12 | -429.55 | 6.76 | 6.46 | 1.30 | -3358.00% | -10000.00% | 6994.00% | -9.83% | -1.89 | -137.82% | 0.00% | 0.00% | 5.59% | -6.82 | -7.56 | — | 3.95 |
| VIR | Vir Biotechnology, Inc. | $9.09 | 1.26B | +144% | -52% | — | — | -2.95 | 1.69 | 18.87 | -2.39 | — | 1.75 | 82.92% | -682.68% | -638.87% | -45.73% | -112.47% | -36.47% | 0.24 | — | 5.54 | 5.03 | 0.11 | -1749.00% | -761.00% | -1257.00% | -30.66% | -4.22 | -95.31% | 0.00% | 0.00% | 0.00% | -2.17 | -2.57 | 14.85 | 0.63 |
About Castle Biosciences, Inc.
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
- CEO
- Derek J. Maetzold
- Employees
- 784
- Beta
- 1.06
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($20.66 ÷ $24.81) − 1 = -16.73% (DCF, example).